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P ediatric Hodgkin’s lymphoma (HL) accounts for approximately 4% of cases of pediatric cancer overall and 40% of cases of malignant lymphoma in Western countries; the incidence is lower in Japan.  In 
the 1970s,  combination chemotherapy was demon-
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This trial enrolls patients with untreated Hodgkin’s lymphoma aged < 20 years at diagnosis and examines the 
effects of omitting radiation therapy if the FDG-positron emission tomography (PET) findings after two com-
pleted cycles of combination chemotherapy are negative.  It thereby aims to determine whether patients who 
truly require radiation therapy can be identified by FDG-PET.  If so,  this modality could be used to omit radia-
tion therapy for all other patients,  decreasing the risk of serious long-term complications without affecting 
survival rates.  The outcomes of patients for whom FDG-PET is used to assess early treatment response will also 
be determined.
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strated to be an effective treatment,  and the concomi-
tant use of irradiation yielded high cure rates.  However,  
this led to serious long-term complications (gonadal 
disorders,  second cancers,  cardiac disorders,  pulmo-
nary disorders,  etc.) and non-tumor-related deaths [1].  
Therefore,  since the 1990s,  clinical trials have been 
conducted (primarily in the West) with the goal of 
reducing long-term complications (i.e., alleviating the 
burden of treatment) while maintaining high survival 
rates.
An increasing number of attempts are being made to 
omit irradiation in the treatment of pediatric HL 
[2-5]; some trials have demonstrated that among 
patients who have achieved a complete response (CR) 
through chemotherapy,  the overall survival (OS) of 
those for whom irradiation was omitted is at least equal 
to that of patients who undergo irradiation.  However,  
to date,  no prospective clinical trial for pediatric HL has 
been designed or conducted in Japan.
Positron emission tomography (PET) is an essential 
tool for assessing the initial staging of cancers,  includ-
ing lymphoma,  and therapeutic responses.  Recent 
prospective clinical trials of HL have already used PET 
after completing 2-3 cycles of combination chemother-
apy (interim PET),  and incorporated it to change the 
content of treatment during the treatment course.  
However,  there is currently little evidence that PET-
guided changes in therapeutic strategies lead to improved 
therapeutic outcomes; hence,  such changes must be 
assessed with a clinical trial.
Among pediatric clinical trials that attempted omis-
sion of radiotherapy,  the actual omission rate was 
29.9% in the COG 5942 study (in which all risk cases 
were enrolled and irradiation was performed only for 
non-CR cases) [2],  10.8% in the GPOH HD 2002 study 
(all risk cases were enrolled and irradiation was per-
formed only for non-CR cases with low-risk) [4],  
38.8% in the COG 59704 study (high-risk cases were 
enrolled and irradiation was performed only for 
non-CR cases) [5],  and 53.4% in the Stanford,  St. Jude 
and Dana Farber consortium (low-risk cases were 
enrolled and irradiation was performed only for 
non-CR cases) [3],  respectively.  Some of these trials 
reported that the OS was equivalent between cases 
using chemotherapy with radiation and those using 
chemotherapy without radiation therapy.
Endpoints
The primary endpoint of the present study is the 
event free survival (EFS) rate at 5 years.  EFS is defined 
as the duration from the day of registration in the study 
until the first day of remission-induction failure,  relapse,  
secondary-cancer,  or death.  If there are no events,  the 
patients will be censored at the final day of observation.  
The day of event for remission-induction failure is the 
day of registration in the study.  The day of event for 
secondary-cancer or relapse is the assessment day for 
evaluation.
The secondary endpoints are: (1) overall survival 
(OS) rate at 5 years; (2) proportion of complete response 
(CR) at either PET2 or PET3; (3) OS and EFS in the 
irradiation group; (4) OS and EFS in the no-irradiation 
group; (5) the proportion of patients with negative 
interim PET results (the proportion not undergoing 
irradiation); (6) assessment of diagnosis (agreement 
between conventional testing using CT/magnetic reso-
nance imaging [MRI]) and FDG-PET); (7) assessment 
of response at end of treatment (agreement between 
conventional testing using CT/MRI and FDG-PET);  
(8) incidence of complications (pulmonary disorders,  
cardiac disorders,  failure to thrive,  hypothyroidism,  
gonadal disorders,  and second cancers) during the fol-
low-up period; (9) incidence of adverse events; and 
(10) associations between serum cytokine levels and 
outcomes.
Eligibility Criteria
Inclusion criteria. Patients who fulfilled all of the 
following criteria were deemed eligible: (1) histological 
diagnosis of HL,  (2) age < 20 years at diagnosis,  (3) 
completed prior-case registration to the JPLSG CHM-
14 study,  and (4) consent from the patient or their 
guardian based on sufficient verbal and written expla-
nation.
Exclusion criteria. Patients to whom any of the 
following applied were excluded from registration.  (1) 
Hepatic,  renal,  or cardiac dysfunction that would 
interfere with trial treatment.  This assessment was 
based on the following laboratory values obtained 
within 14 days prior to or on the day of registration:  
Total bilirubin level ≥ 3 times the reference value for the 
patient’s age; creatinine level ≥ 3 times the reference 
value for the patient’s age; serious cardiac abnormali-
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ties requiring treatment,  as detected by electrocardiog-
raphy; and a Lansky score [6] < 30 (however,  if deteri-
oration in the Lansky score is believed to be due to HL,  
a score as low as 10 is acceptable).  (2) Past use of anti-
cancer agents and/or irradiation.  (3) Degenerative cen-
tral nervous system lesions.  (4) Intracranial bleeding 
that would interfere with treatment (Common 
Terminology Criteria for Adverse Events (CTCAE) ver.  
4.0; grade ≥ 3).  (5) Difficult-to-control infections 
(including active pneumonia and human immunodefi-
ciency virus infection,  the latter determined by anti-
body testing).  (6) Current pregnancy or potential preg-
nancy.  (7) Lactating women.  (8) Past history of 
malignant neoplasm or multiple cancers.  (9) Past his-
tory of congenital or acquired immunodeficiency syn-
drome.  (10) Deemed ineligible for any other reason,  as 
determined by the investigator.
Methods
Study design. This is a multicenter,  single-treat-
ment trial of the risk-adapted omission of irradiation 
for patients with negative PET results,  following an 
initial treatment response to combination chemother-
apy.  The trial is registered with the University Hospital 
Medical Information Network (UMIN) clinical trial 
registration system (UMIN000019093).  The protocol 
for the present trial was reviewed and approved by the 
Institutional Review Board of the Japanese Society of 
Pediatric Hematology/Oncology.
Intervention. All patients will undergo FDG-
PET as many as 3 times: prior to starting treatment 
(PET1); during treatment,  after completing 2 cycles of 
chemotherapy (PET2); and after the conclusion of 
treatment (PET3) (see Fig . 1).  Low-risk patients (IA,  
IB,  IIA) will undergo 2 cycles of OEPA (vincristine,  
etoposide,  prednisolone,  and doxorubicin) (boys) or 
OPPA (vincristine,  procarbazine,  prednisolone,  and 
doxorubicin) (girls); if PET2 results are negative,  treat-
ment is concluded and no irradiation will be given.  
Intermediate-risk patients (IEA,  IEB,  IIEA,  IIB,  IIIA) 
will undergo 2 cycles of OEPA (boys) or OPPA (girls) 
and 2 cycles of COPDAC (cyclophosphamide,  vincris-
tine,  prednisolone,  and dacarbazine) (boys) or COPP 
(cyclophosphamide,  vincristine,  procarbazine,  and 
prednisolone) (girls); if the PET2 results are negative,  
treatment is concluded and no irradiation will be given.  
High-risk patients (IIEB,  IIIEA,  IIIEB,  IIIB,  IVA,  
IVB) will undergo 2 cycles of OEPA (boys) or OPPA 
(girls) and 4 cycles of COPDAC (boys) or COPP 
(girls); if the PET2 results are negative,  treatment is 
concluded and no irradiation will be given.  All patients 
with positive PET2 results will undergo involved-field 
irradiation,  or involved-site or node irradiation (20-36 
Gy) following completion of chemotherapy.  To balance 
the risk of irradiation with the long-term complications 
that can result from the intensification of chemotherapy 
to compensate for the omission of radiation,  the frame-
work of the chemotherapy regimen in the present study 
is based on that used in the GPOH-02 study [4],  in 
which cardiotoxicity and infertility were successfully 
reduced by omitting radiation therapy for CR cases of 
low-risk patients and by substituting a less gonadotoxic 
alkylating agent,  dacarbazine,  for procarbazine for 
boys,  without compromising outcomes.  
The results of PET scans will be interpreted in cen-
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Fig. 1　 COPDAC,  cyclophosphamide,  vin-
cristine,  prednisolone,  dacarbazine; COPP,  
cyclophosphamide,  vincristine,  procarbazine,  
prednisolone; OEPA,  vincristine,  etoposide,  
prednisolone,  doxorubicin; OPPA,  vincristine,  
procarbazine,  prednisolone,  doxorubicin.
tral review using the Deauville criteria (a 5-point scale) 
[7].  For patients who discontinue protocol treatment or 
do not undergo PET,  no treatment will be pre-
scribed; however,  these patients will be followed up.
Statistical Considerations
Sample size. In a retrospective study conducted 
in Japan,  the EFS rate at 5 years of patients with HL was 
81.5% for the overall population and 73% for the inter-
mediate-to-high-risk population.  In the present study,  
we presume that the EFS should be at least as high as 
that of intermediate-to-high-risk patients; therefore,  
the threshold EFS rate was set at 73% [8].  Also,  
non-Japanese studies that have attempted to reduce the 
use of irradiation have reported EFS rates at 5 years of 
78-96%; in the GPOH-HD 2002 study,  which is similar 
to the PET-based early diagnosis used in the present 
trial,  the EFS rate at 5 years was 89% [4].  Therefore,  
the expected EFS rate was set at 89%.  Assuming a 
5-year registration period and 5-year follow-up period,  
and using a level of statistical significance of 0.05 (one-
tailed) and power of 90%,  nonparametric calculation 
revealed that a sample size of 47 patients was necessary.  
Taking dropouts into account,  the number of patients 
was set at 50.
Analysis set. The efficacy analysis set is the full 
analysis set.  It comprises registered eligible patients 
who began the protocol treatment,  excluding the fol-
lowing: registered patients later deemed ineligible,  and 
incorrectly registered patients.  The safety analysis set 
comprises patients for whom protocol treatment was 
begun following registration.
Statistical analysis. EFS and OS rates will be 
estimated using the Kaplan-Meier method,  overall and 
stratified according to whether irradiation was given or 
omitted.  The 90% CI for yearly survival rates will be 
calculated using Greenwood’s formula.  The confidence 
interval of the proportion of CR will be calculated based 
on the binomial distribution.  For PET positive/negative 
results and CR achievement/non-achievement at diag-
nosis and assessment of response at the end of treat-
ment,  the agreement,  sensitivity,  specificity,  and posi-
tive and negative predictive values will be calculated.  
The effect of serum cytokine levels at diagnosis on EFS 
will be examined using a Cox proportional hazard 
model.  The incidence of severe adverse events (grade 
≥ 3) and of complications occurring during follow-up 
will also be calculated.
Discussion
The present study aims to determine,  within the 
confines of safety,  whether assessing treatment response 
using PET (which is highly sensitive and specific) 
enables the identification of patients who truly require 
radiation therapy,  thereby enabling omission of radia-
tion therapy for all other patients without affecting sur-
vival rates.  The present study also aims to determine 
pediatric HL treatment outcomes in patients for whom 
FDG-PET is used to assess early treatment response.  
This is anticipated to lead to the development of alter-
native therapeutic methods with fewer long-term com-
plications.
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